GlaxoSmithKline Stock Hits New 52-Week High (GSK)

NEW YORK ( TheStreet) -- GlaxoSmithKline (NYSE: GSK) hit a new 52-week high Thursday as it is currently trading at $46.86, above its previous 52-week high of $46.50 with 539,727 shares traded as of 9:35 a.m. ET. Average volume has been 2.1 million shares over the past 30 days.

GlaxoSmithKline has a market cap of $113.66 billion and is part of the health care sector and drugs industry. Shares are up 1.6% year to date as of the close of trading on Wednesday.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. The company has a P/E ratio of 13.8, below the average drugs industry P/E ratio of 14 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally poor debt management on most measures that we evaluated. You can view the full GlaxoSmithKline Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

These Stocks Pay You to Own Them

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Hikma Sinks on Advair Generic Concerns

Shire Gains as it Seeks European Approval For Dry Eye Treatment